新冠肺炎对黄斑新生血管形成和视网膜静脉阻塞治疗的影响:单中心经验。

Biomedicine Hub Pub Date : 2021-12-08 eCollection Date: 2021-09-01 DOI:10.1159/000519565
Rodrigo Vilares-Morgado, Carolina Madeira, Ana Maria Cunha, Manuel Falcão, João Beato, Ana Catarina Pedrosa, Susana Penas, Elisete Brandão, Fernando Falcão-Reis, Ângela Carneiro
{"title":"新冠肺炎对黄斑新生血管形成和视网膜静脉阻塞治疗的影响:单中心经验。","authors":"Rodrigo Vilares-Morgado,&nbsp;Carolina Madeira,&nbsp;Ana Maria Cunha,&nbsp;Manuel Falcão,&nbsp;João Beato,&nbsp;Ana Catarina Pedrosa,&nbsp;Susana Penas,&nbsp;Elisete Brandão,&nbsp;Fernando Falcão-Reis,&nbsp;Ângela Carneiro","doi":"10.1159/000519565","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The aim of this study was to evaluate whether the coronavirus disease 19 (COVID-19) pandemic resulted in undertreatment and subsequent loss of visual acuity (VA) in patients with macular neovascularization (MNV) or retinal vein occlusion (RVO) regularly treated with intravitreal antivascular endothelial growth factor injections.</p><p><strong>Methods: </strong>Single-center, retrospective study of patients scheduled for treatment between March 19 and June 1, 2020, the national mandatory quarantine period. Patients' demographics, VA, and scheduled treatment during this period were reviewed via medical records. All patients were analyzed regarding treatment attendance rates. The visual impact of COVID-19 was assessed in patients who had been treated and presented a stable VA for >6 months before the beginning of the quarantine.</p><p><strong>Results: </strong>This study included 927 eyes from 769 patients. The attendance rate increased throughout the study timeframe (<i>p</i> < 0.001) and correlated negatively with higher patient's age (<i>r</i> = -0.142; <i>p</i> = 0.005). Patients with age-related macular degeneration (67.6%) had lower attendance rates (<i>p</i> = 0.007) and were older (<i>p</i> < 0.001). The visual impact analysis included 400 eyes from 325 patients. The average VA variation throughout this period was -1.7 ± 8.4 ETDRS letters and was similar in different retinal pathologies (<i>p</i> = 0.334). VA variation did not correlate with the number of missed treatments per patient (<i>r</i> = 0.100; <i>p</i> = 0.150). The prevalence of subretinal fluid and intraretinal fluid, as well as central retinal thickness decreased significantly throughout the study period (<i>p</i> values of <0.001, <0.001, and 0.032, respectively).</p><p><strong>Conclusion: </strong>The COVID-19 pandemic had a significant impact on the attendance rate of patients with MNV or RVO to their scheduled treatments, which was higher in the first week of mandatory quarantine. Nevertheless, VA did not decrease significantly during this period, with a limited VA variation regardless of primary retinal disorder and morphological parameters even improved in the eyes included in the visual impact analysis.</p>","PeriodicalId":9075,"journal":{"name":"Biomedicine Hub","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740216/pdf/bmh-0006-0145.pdf","citationCount":"0","resultStr":"{\"title\":\"Covid-19 Impact on Macular Neovascularization and Retinal Vein Occlusion Treatment: Single-Center Experience.\",\"authors\":\"Rodrigo Vilares-Morgado,&nbsp;Carolina Madeira,&nbsp;Ana Maria Cunha,&nbsp;Manuel Falcão,&nbsp;João Beato,&nbsp;Ana Catarina Pedrosa,&nbsp;Susana Penas,&nbsp;Elisete Brandão,&nbsp;Fernando Falcão-Reis,&nbsp;Ângela Carneiro\",\"doi\":\"10.1159/000519565\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>The aim of this study was to evaluate whether the coronavirus disease 19 (COVID-19) pandemic resulted in undertreatment and subsequent loss of visual acuity (VA) in patients with macular neovascularization (MNV) or retinal vein occlusion (RVO) regularly treated with intravitreal antivascular endothelial growth factor injections.</p><p><strong>Methods: </strong>Single-center, retrospective study of patients scheduled for treatment between March 19 and June 1, 2020, the national mandatory quarantine period. Patients' demographics, VA, and scheduled treatment during this period were reviewed via medical records. All patients were analyzed regarding treatment attendance rates. The visual impact of COVID-19 was assessed in patients who had been treated and presented a stable VA for >6 months before the beginning of the quarantine.</p><p><strong>Results: </strong>This study included 927 eyes from 769 patients. The attendance rate increased throughout the study timeframe (<i>p</i> < 0.001) and correlated negatively with higher patient's age (<i>r</i> = -0.142; <i>p</i> = 0.005). Patients with age-related macular degeneration (67.6%) had lower attendance rates (<i>p</i> = 0.007) and were older (<i>p</i> < 0.001). The visual impact analysis included 400 eyes from 325 patients. The average VA variation throughout this period was -1.7 ± 8.4 ETDRS letters and was similar in different retinal pathologies (<i>p</i> = 0.334). VA variation did not correlate with the number of missed treatments per patient (<i>r</i> = 0.100; <i>p</i> = 0.150). The prevalence of subretinal fluid and intraretinal fluid, as well as central retinal thickness decreased significantly throughout the study period (<i>p</i> values of <0.001, <0.001, and 0.032, respectively).</p><p><strong>Conclusion: </strong>The COVID-19 pandemic had a significant impact on the attendance rate of patients with MNV or RVO to their scheduled treatments, which was higher in the first week of mandatory quarantine. Nevertheless, VA did not decrease significantly during this period, with a limited VA variation regardless of primary retinal disorder and morphological parameters even improved in the eyes included in the visual impact analysis.</p>\",\"PeriodicalId\":9075,\"journal\":{\"name\":\"Biomedicine Hub\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-12-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740216/pdf/bmh-0006-0145.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomedicine Hub\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1159/000519565\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/9/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedicine Hub","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000519565","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/9/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

目的:本研究的目的是评估冠状病毒病19 (COVID-19)大流行是否导致黄斑新生血管(MNV)或视网膜静脉闭塞(RVO)患者定期接受玻璃体内抗血管内皮生长因子注射治疗的治疗不足和随后的视力丧失(VA)。方法:对2020年3月19日至2020年6月1日国家强制隔离期间就诊的患者进行单中心回顾性研究。在此期间,通过医疗记录对患者的人口统计、VA和计划治疗进行了审查。分析所有患者的治疗出勤率。在隔离开始前6个月以上接受治疗并出现稳定VA的患者中,评估了COVID-19的视觉影响。结果:本研究纳入769例患者927只眼。出勤率在整个研究期间呈上升趋势(p < 0.001),且与患者年龄越高呈负相关(r = -0.142;P = 0.005)。年龄相关性黄斑变性患者(67.6%)的出勤率较低(p = 0.007)且年龄较大(p < 0.001)。视觉影响分析包括325名患者的400只眼睛。这一时期的平均VA变化为-1.7±8.4 ETDRS字母,在不同的视网膜病理中相似(p = 0.334)。VA变化与每位患者的错过治疗次数无关(r = 0.100;P = 0.150)。结论:新冠肺炎大流行对MNV或RVO患者的计划治疗出勤率有显著影响,在强制隔离的第一周更高。然而,在此期间,VA并没有显著下降,无论原发性视网膜疾病和视觉影响分析中包括的眼睛的形态学参数,VA变化有限,甚至有所改善。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Covid-19 Impact on Macular Neovascularization and Retinal Vein Occlusion Treatment: Single-Center Experience.

Covid-19 Impact on Macular Neovascularization and Retinal Vein Occlusion Treatment: Single-Center Experience.

Purpose: The aim of this study was to evaluate whether the coronavirus disease 19 (COVID-19) pandemic resulted in undertreatment and subsequent loss of visual acuity (VA) in patients with macular neovascularization (MNV) or retinal vein occlusion (RVO) regularly treated with intravitreal antivascular endothelial growth factor injections.

Methods: Single-center, retrospective study of patients scheduled for treatment between March 19 and June 1, 2020, the national mandatory quarantine period. Patients' demographics, VA, and scheduled treatment during this period were reviewed via medical records. All patients were analyzed regarding treatment attendance rates. The visual impact of COVID-19 was assessed in patients who had been treated and presented a stable VA for >6 months before the beginning of the quarantine.

Results: This study included 927 eyes from 769 patients. The attendance rate increased throughout the study timeframe (p < 0.001) and correlated negatively with higher patient's age (r = -0.142; p = 0.005). Patients with age-related macular degeneration (67.6%) had lower attendance rates (p = 0.007) and were older (p < 0.001). The visual impact analysis included 400 eyes from 325 patients. The average VA variation throughout this period was -1.7 ± 8.4 ETDRS letters and was similar in different retinal pathologies (p = 0.334). VA variation did not correlate with the number of missed treatments per patient (r = 0.100; p = 0.150). The prevalence of subretinal fluid and intraretinal fluid, as well as central retinal thickness decreased significantly throughout the study period (p values of <0.001, <0.001, and 0.032, respectively).

Conclusion: The COVID-19 pandemic had a significant impact on the attendance rate of patients with MNV or RVO to their scheduled treatments, which was higher in the first week of mandatory quarantine. Nevertheless, VA did not decrease significantly during this period, with a limited VA variation regardless of primary retinal disorder and morphological parameters even improved in the eyes included in the visual impact analysis.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信